己基(丙基)胺 | 20193-23-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 己基(丙基)胺
• 英文名称: N-propylhexylamine
• 英文别名: N-ethyl-methylhexanamine；Hexylamine, N-propyl-；N-propylhexan-1-amine
• CAS: 20193-23-1
• 化学式: C₉H₂₁N
• mdl: MFCD11161722
• 分子量: 143.272
• InChiKey: WBLXZSQLBOFHAB-UHFFFAOYSA-N

物化性质

• 沸点：
  171-181 °C(Press: 753 Torr)
• 密度：
  0.770±0.06 g/cm3(Predicted)
• 保留指数：
  1047

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为反应物：
  描述：

  己基(丙基)胺 、 2-氯-N,N-二甲基乙胺 在 xylene 作用下， 生成 N-hexyl-N',N'-dimethyl-N-propyl-ethylenediamine
  参考文献：
  名称：

  Derivatives of Dimethylaminoethanol and Dimethylaminoethylamine

  摘要：

  DOI：

  10.1021/ja01125a050
• 作为产物：
  描述：

  N-苄基-N-己基胺 在 氢氧化钾 作用下， 生成 己基(丙基)胺
  参考文献：
  名称：

  72.抗血浆作用和化学成分。第五部分衍生自6-甲氧基喹啉的甲醇胺

  摘要：

  DOI：

  10.1039/jr9420000401

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
  申请人：REMYND NV

  公开号：WO2016083490A1

  公开（公告）日：2016-06-02

  This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。
• Catalytic Hydrogenation of Amides to Amines under Mild Conditions
  作者：Mario Stein、Bernhard Breit

  DOI：10.1002/anie.201207803

  日期：2013.2.18

  Under (not so much) pressure: A general method for the hydrogenation of tertiary and secondary amides to amines with excellent selectivity using a bimetallic Pd–Re catalyst has been developed. The reaction proceeds under low pressure and comparatively low temperature. This method provides organic chemists with a simple and reliable tool for the synthesis of amines.

  在（不是很大）压力下：已开发出一种使用双金属Pd-Re催化剂将叔酰胺和仲酰胺氢化成胺的通用方法，具有优异的选择性。反应在低压和较低温度下进行。该方法为有机化学家提供了一种简单可靠的胺合成工具。
• Biocatalytic <i>N</i>-Alkylation of Amines Using Either Primary Alcohols or Carboxylic Acids via Reductive Aminase Cascades
  作者：Jeremy I. Ramsden、Rachel S. Heath、Sasha R. Derrington、Sarah L. Montgomery、Juan Mangas-Sanchez、Keith R. Mulholland、Nicholas J. Turner

  DOI：10.1021/jacs.8b11561

  日期：2019.1.23

  The alkylation of amines with either alcohols or carboxylic acids represents a mild and safe alternative to the use of genotoxic alkyl halides and sulfonate esters. Here we report two complementary one-pot systems in which the reductive aminase (RedAm) from Aspergillus oryzae is combined with either (i) a 1° alcohol/alcohol oxidase (AO) or (ii) carboxylic acid/carboxylic acid reductase (CAR) to affect

  胺与醇或羧酸的烷基化代表了使用遗传毒性烷基卤化物和磺酸酯的温和且安全的替代方案。在这里，我们报告了两种互补的一锅系统，其中来自米曲霉的还原胺酶 (RedAm) 与 (i) 1° 酒精/酒精氧化酶 (AO) 或 (ii) 羧酸/羧酸还原酶 (CAR) 结合影响 N-烷基化反应。两种方法的应用都在底物范围和制备规模合成方面得到了举例说明。这些新的生物催化方法解决了替代传统合成方案面临的问题，例如苛​​刻的条件、过度烷基化和复杂的后处理程序。
• [EN] 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS<br/>[FR] 4-ARYL-2-ANILINO-PYRIMIDINES COMME INHIBITEURS DE PLK KINASES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009112439A1

  公开（公告）日：2009-09-17

  The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及式(Ia)或(Ib)的化合物，其N-氧化物形式，药学上可接受的加盐物，季铵盐，立体异构体，互变异构体，消旋体，代谢物，前药，水合物或其溶剂化合物，其中Y1，m，n，R1；X1；X2；R2；X3；X4；R3；和R4在权利要求中定义的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及激酶抑制剂，用于治疗由激酶介导的疾病状态，特别是PLK4，特别是对治疗涉及异常细胞增殖的病理过程有用的化合物，如肿瘤生长、类风湿关节炎、再狭窄和动脉粥样硬化。
• [EN] OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'OXADIAZOLE
  申请人：REMYND NV

  公开号：WO2015140130A1

  公开（公告）日：2015-09-24

  The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

  本发明涉及式(I)或(II)的化合物或其立体异构体、对映体、消旋体或互变异构体，其中R1、R2、R3、L1、L2、L3、L4、L5和n的含义与权利要求和说明中定义的含义相同。本发明还涉及包含这些化合物的组合物，特别是药物，以及利用这些化合物和组合物预防和/或治疗代谢紊乱和/或神经退行性疾病和/或蛋白质错折性疾病的用途。